Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 59 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... November 30, 2023 In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer January 12, 2023 FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC November 25, 2022 Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT... January 10, 2024 Load more HOT NEWS Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris How to Get Started With Meditation During Cancer Pink Van Makes the Rounds Throughout Rural New Zealand to Offer...
